Introduction {#S1}
============

According to the 2016 UNAIDS report, approximately 150,000 pediatric infections occur annually, accounting for \~10% of new global HIV-1 infections ^[@R1]^. The benefits of breastfeeding to infant health are well recognized, yet vertical transmission of HIV-1 via breastfeeding results in nearly half of the annual mother-to-child-transmission (MTCT) occurrences ^[@R2]^. In resource-limited areas, formula-fed infants exhibit high mortality rates due to respiratory and diarrheal illnesses ^[@R3],\ [@R4]^ and thus, formula feeding is not a viable strategy to reduce pediatric HIV transmissions. While administration of antiretroviral therapy (ART) to HIV-1 infected, breastfeeding mothers reduces MTCT rates to below 5% ^[@R5]^, socioeconomic barriers to ART access and compliance ^[@R6],\ [@R7]^, as well as acute maternal infections make it unlikely that ART alone can achieve eradication of pediatric HIV-1 ^[@R8]--[@R10]^. Therefore, developing effective immune-based prevention strategies, such as a maternal or infant vaccine to protect infants from oral HIV-1 acquisition during breastfeeding, may greatly contribute to the goal of achieving an HIV-free generation ^[@R11]^.

Despite repeated, daily mucosal HIV exposure during years of breastfeeding, only \~10% of breastfeeding infants of untreated HIV-infected mothers acquire HIV ^[@R11]^, suggesting the presence of protective factors in milk. The role of innate factors such as mucins ^[@R12]^, defensins ^[@R13]^, lactoferrin ^[@R14]^, long chain fatty acids ^[@R15]^, IL-15 ^[@R16]^, and tenascin C ^[@R17]^ present in breast milk have been extensively studied for their anti-HIV activity. Additionally, the milk microbiome, particularly lactobacillus and pediococcal species, have been reported to inhibit HIV infection of target cells ^[@R18]^. In chronically HIV-infected mothers, breast milk also contains HIV-1 envelope (Env)-specific antibodies and Env-specific memory B cells ^[@R19],\ [@R20]^, which are primarily IgG1 isotype and are otherwise similar in specificity and function to those identified in blood of chronically infected individuals ^[@R21]^. While breast milk antibodies capable of ADCC have been associated with diminished vertical transmission rates ^[@R22]^ and reduced infant mortality after infection ^[@R23]^ in humans, the protective capabilities of polyfunctional milk antibodies remain unclear. Induction or passive infusion of broadly neutralizing antibodies (bNAbs) is an attractive immunologic strategy for global HIV control (reviewed in ^[@R24]^) including in the setting of postnatal HIV transmission ^[@R25],\ [@R26]^. Yet, bNAbs only develop naturally in fewer than 20% of individuals, typically take 2--4 years to develop after infection ^[@R27]^, and have been unable to be elicited through vaccination. Moreover, bNAbs have not been identified in breast milk ^[@R19],\ [@R28]^. Thus, the contribution of non- and weakly-neutralizing breast milk antibodies to the inefficiency of HIV-1 transmission through breastfeeding warrants further exploration.

In this study, we sought to define the impact of systemic and orally administered natural breast milk-derived maternal HIV Env-specific monoclonal antibodies (mAbs) with non- and weakly-neutralizing functions on infant oral virus acquisition and dissemination in the periphery and lymphoid tissues. MAbs selected for this study were isolated from milk B cells of a cohort of HIV-1-infected Malawian women and were intended to represent IgG antibodies with various antiviral functionalities and specificities of those commonly found in breast milk (ADCC, tier 1 and weak tier 2 neutralization, dendritic cell-virus binding inhibition, epithelial cell-virus binding inhibition, and C1, V3, CD4-blocking) ^[@R19],\ [@R28],\ [@R29]^. RMs were passively infused with the maternal breast milk mAbs to mimic antibody transfer via the placenta, and then repeatedly fed infant formula containing the maternal breast milk-derived mAbs, and low dose tier 2 chimeric simian/human immunodeficiency virus, SHIV-1157ipd3N4 ^[@R30]^. Defining the contributions of non-broadly neutralizing breast milk-derived antibodies to protection against transmission of HIV-1 through breastfeeding may inform the design of maternal and infant vaccines aimed at eliminating postnatal HIV-1 infections and limiting the size of the latent viral reservoir in the setting of breakthrough infections.

Results {#S2}
=======

Selection of maternal breast milk mAbs for in vivo evaluation in infant monkeys and study design. {#S3}
-------------------------------------------------------------------------------------------------

The HIV-1 Env-specific mAbs isolated from breast milk B cells of lactating, HIV-1-infected Malawian women ^[@R20]^ and selected for infusion into infant RMs in this study were initially characterized based on binding specificity, epithelial and dendritic cell-virus binding inhibition, ADCC, and neutralization against the tier 2 challenge virus in this study, SHIV-1157ipd3N4 ^[@R30]^, as well as neutralization of several tier 1 HIV/SHIV variants ([Figure 1A](#F1){ref-type="fig"}) ^[@R28]^. As previously reported, all of the mAbs isolated from milk B cells were IgG1, did not demonstrate broadly neutralizing activity, and had similar characteristics to those isolated from peripheral blood HIV-1 Env-specific B cells ^[@R20]^. The infusion mAbs were selected based on their diversity of functions and specificities; mAb DH378 demonstrated CD4-blocking capability associated with CD4 binding site (CD4bs)-specificity and mAb DH377 bound to linear and conformational variable loop 3 (V3) binding, specificities previously associated with decreased MTCT risk ^[@R31],\ [@R32]^, and mAb DH382 was constant region 1 (C1)-specific and competed with mAb A32-Env binding. MAbs DH378 and DH377 were able to block epithelial and dendritic cell-virus binding in vitro ^[@R28]^. Unsurprisingly, the A32-like mAb DH382 mediated potent ADCC activity against the tier 2 challenge SHIV-1157ipd3N4, with a maximum % specific killing of 40.7% and an endpoint concentration of \<0.04µg/mL. Both DH378 and DH377 neutralized all tier 1 viruses tested, including SHIV SF162P4, SHIV BaL-P4, MW965.26, and SHIV-1157ipEL-p. Yet, DH378, but not DH377, demonstrated weak neutralization activity against the tier 2 clade C SHIV challenge virus when tested at high concentration (SHIV-1157ipd3N4 neutralization; DH378 IC~50~=79µg/mL, DH377 IC~50~\>100 µg/mL).

To assess the degree to which common HIV Env-specific polyfunctional milk antibodies contribute to protection against oral virus acquisition and replication, 20 infant RMs were divided into 2 anti-HIV-1 Env-specific breast milk mAb treatment groups (n=6) and a control mAb treatment group (n=8) for passive mAb infusion and oral SHIV-1157ipd3N4 challenge ([Figure 1B](#F1){ref-type="fig"}). In this study scheme, systemic passive infusion was intended to simulate placental IgG transfer, while the oral inoculum was intended to represent oral exposure to the combination of milk HIV Env-specific antibodies at physiologic levels with infectious virus ^[@R19]^. The first treatment group consisted of 6 animals treated with DH378, the weakly neutralizing mAb against the tier 2 challenge SHIV. The second group consisted of 6 animals treated with an equimolar mixture of mAbs DH378, DH377, and DH382---a mixture containing mAbs with binding specificities including a specificity previously associated with decreased MTCT (V3) ^[@R31],\ [@R32]^, ADCC activity, dendritic and epithelial cell-virus binding inhibition, and weak tier 2 neutralization against the challenge SHIV. Anti-influenza hemagglutinin (HA) mAb CH65 was employed as a control mAb treatment in 8 animals, including total mAb dose controls for each anti-HIV mAb treatement group (10mg/kg CH65 in n=6 animals; 30mg/kg CH65 in n=2 animals). To simulate placental maternal Ab transfer, infants were infused intravenously with the mAbs 1 hour prior to the first of 9 oral SHIV-1157ipd3N4/mAb combination challenges in formula (3 times/day for 3 consecutive days). Animals were reinfused with the same mAb dose on day 7 to sustain detectable systemic mAb levels for at least 2 weeks after virus challenge. SHIV-challenged infant monkeys were then followed for plasma mAb kinetics, systemic cell-free and cell-associated virus loads, and were necropsied at 8 weeks for assessment of lymphoid and GI tract tissue viral loads ([Figure 1B](#F1){ref-type="fig"}).

Pharmacokinetics of maternal milk HIV-1 mAb infusion of infant RM serum and saliva. {#S4}
-----------------------------------------------------------------------------------

Serum mAb concentrations at longitudinal time points through 8 weeks post SHIV-challenge were measured by ELISA to determine the kinetics of the mAb persistence. Serum mAb levels in animals from all treatment groups were similar through 2 weeks post-infusion, achieving peak concentrations of 9.2×10^4^- 4.5×10^6^ ng/mL and variable rates of mAb clearance, presumably due to variability of the infant immune response against the recombinant mAb and clearance rates ([Figure 2A-C](#F2){ref-type="fig"}; [Figure S1](#SD1){ref-type="supplementary-material"}).

Plasma neutralizing antibody (NAb) and ADCC levels were measured to assess in vivo functionality of the infused treatment mAbs and the development of host humoral responses ([Figure 2B, C](#F2){ref-type="fig"}). Predictably, NAb responses against the tier 1 clade C virus MW965 were high in all DH378- and tri-mAb-treated animals early after mAb infusion, and the magnitude of the responses declined to undetectable in some animals as early as 6 weeks post challenge when circulating mAb levels declined ([Figure 2D](#F2){ref-type="fig"}). Interestingly, several control animals (LH20, LI52, LD65, LD77, LL15) developed tier 1, MW965 NAb responses as early as 6 weeks post-challenge. None of the animals had detectable plasma neutralization against either the tier 2 SHIV-1157ipd3N4 challenge virus or the related tier 1 virus SHIV-1157ipEL-p ^[@R33]^ at peak mAb concentrations or 8 weeks post challenge, which was unsurprising as serum mAb concentrations never surpassed that of the in vitro IC~50~ ([Figure 1A](#F1){ref-type="fig"}). Serum ADCC endpoint titers against SHIV-1157ipd3N4-infected CD4+ T cells were measured preinfusion, at peak infusion mAb concentration (1 day after second infusion), and at 8 weeks post infection for control and mAb-treated RMs ([Figure 2E](#F2){ref-type="fig"}). As expected, serum from tri-mAb-treated animals exhibited high magnitude ADCC function (mean endpoint dilution=12,303), which deteriorated by 8 weeks post initial infusion to undetectable levels. Two of 6 DH378-treated animals demonstrated low magnitude ADCC function detectable at peak mAb levels (mean endpoint dilution=175), comparable to that of background levels detected in some infants ([Figure 2E](#F2){ref-type="fig"}). Notably, 2 of 8 control mAb-treated and 1 of 6 DH378-treated animals, but none of the tri-mAb-infused infant RMs, developed detectable autologous ADCC-mediating mAbs against the challenge SHIV strain after infection at 8 weeks post initial infusion, presumably related to virus load at 8 weeks of infection.

Saliva mAb concentrations were also measured prior to and following oral challenge ([Figure 2F-H](#F2){ref-type="fig"}). All animals demonstrated detectable mAb levels in saliva at 1 hour post infusion, the time of the first SHIV challenge. Saliva mAb levels peaked around 1 day post infusion in all animals and only slightly declined by 7 days post initial infusion in most animals.

Effect of maternal milk HIV-1 antibody treatment on SHIV acquisition and plasma viremia in orally challenged infant RMs. {#S5}
------------------------------------------------------------------------------------------------------------------------

To characterize the effectiveness of the mAb treatments in preventing SHIV acquisition, SHIV plasma viral RNA loads of orally-challenged infant RMs were measured in longitudinal samples by qRT-PCR. 6/8 (75%) CH65-treated control animals, 3/6 (50%) DH378-treated animals, and 2/6 (33%) tri-mAb-treated animals became detectably viremic after 9 oral SHIV challenges resulting in statistically similar systemic SHIV acquisition rates between controls and each treatment group ([Figure 3A](#F3){ref-type="fig"}; FDR corrected Fisher's exact test; Controls vs. DH378 p=0.58, tri-mAb cocktail p=0.55). Peak and set point viral RNA loads in plasma were largely similar between CH65-treated control animals (median and range; peak=6.2×10^6^copies/mL, 9.3×10^5^-2.7×10^7^copies/mL; set point=4.4×10^5^copies/mL, 5.4×10^4^-9.5×10^7^copies/mL) and tri-mAb-treated animals (median and range; peak=2.1×10^6^copies/mL, 5.3×10^5^-3.6×10^6^copies/mL; set point=3.0×10^5^copies/mL, 1.2×10^4^-5.9×10^5^copies/mL) when excluding animals with undetectable plasma viral RNA loads ([Figure 3B](#F3){ref-type="fig"}). Interestingly, the tri-mAb cocktail-treated animal LK81 emerged as an outlier with the lowest plasma peak and set point viral RNA loads observed in a viremic animal from this study (peak=5.3×10^5^copies/mL; set point=1.2×10^4^copies/mL). While set point viral RNA loads in plasma were similar between viremic CH65-treated control animals and viremic DH378-treated animals (median and range; peak=7.7×10^7^copies/mL, 7.4×10^7^- 1.1×10^8^copies/mL; set point=5.1×10^5^copies/mL, 3.5×10^5^-8.9×10^6^copies/mL), the peak viral RNA loads in plasma from viremic DH378-treated animals was significantly higher than that from viremic controls ([Figure 3B](#F3){ref-type="fig"}; FDR-corrected Wilcoxon test; FDR-corrected p=0.05). Given the ranges of peak and set point viral RNA loads, MHC typing was performed to rule out unbalanced MHC types associated with natural control of viremia. Several infants possessed MHC alleles highly (Mamu-A001, Mamu-B017) or weakly (Mamu-A002, Mamu-B047) associated with low set point viral loads and/or longer survival lengths ([Table 1](#T1){ref-type="table"}) ^[@R34]--[@R41]^. Yet, these protective alleles were not more common in any single treatment group (67% for control mAb-, and tri-mAb-treated animals, and 80% for DH378 mAb-treated animals had least 1 protective MHC allele). Additionally, all groups also contained animals with the Mamu-A004 allele, which is associated with increased set point viral loads ^[@R42]^. All viremic, DH378 mAb-treated animals possessed this allele, which could contribute to the significantly higher plasma viral loads observed in these animals ([Figure 3B](#F3){ref-type="fig"}).

Cell-associated SHIV load in blood and tissues from breast milk mAb-treated, orally SHIV-challenged infant RMs. {#S6}
---------------------------------------------------------------------------------------------------------------

To determine whether the presence of pre-existing HIV-1 Env-specific mAbs impacted the cell-associated viral load in blood and tissue compartments following oral challenge in mAb-infused infant RMs, tissue mononuclear cell proviral loads, proportions of viral RNA producing T cells, and tissue-associated infectious virus titers were measured in PBMCs, GI tract, and lymphoid tissues ([Figure 4](#F4){ref-type="fig"}). SHIV provirus in CD4+ T cells in PBMCs (preinfection, 2 and 8 weeks post-infection), GI, and lymphoid tissues at 8 weeks post challenge in viremic infants demonstrated widely variable, but routinely detectable proviral loads (10^4^-10^7^ gag copies/million CD4+ T cells) independent of tissue type or mAb treatment ([Figure 4A](#F4){ref-type="fig"}). SHIV provirus was undetectable in PBMCs or any tissues isolated from tri-mAb-treated animal LK81, which exhibited detectable, albeit relatively low plasma SHIV RNA loads.

The proportion of SHIV RNA transcribing cells as measured by in situ hybridization assays was also similar in lymphoid and GI tissues from animals in all treatment groups. However, mesenteric lymph node and spleen from control mAb-treated animal LL15 exhibited a notably higher prevalence of SHIV RNA positive cells compared to other SHIV-infected infants ([Figure 4B](#F4){ref-type="fig"}). Extensive SHIV RNA production was observed within and surrounding Peyer's patches of the small intestine as well as in CD3+ T cells of lymphoid tissues ([Figure 4C](#F4){ref-type="fig"}). Additionally, SHIV RNA detection within the Peyer's patches largely failed to colocalize with CD3 expression, indicating viral association with dendritic cells and/or other APCs within these germinal centers.

To assess the level of cell-associated infectious SHIV within oral-associated lymphoid and GI tissues at 8 weeks post-challenge, tissue mononuclear cells were cocultured with TZM-bl reporter cells with luminescence output indicating the level of infectious SHIV production ([Figure S2](#SD1){ref-type="supplementary-material"}). In general, tissue-associated infectious SHIV titers were similar between treatment groups ([Figure 4D](#F4){ref-type="fig"}). However, the palatine tonsil exhibited the highest cell-associated infectious titers of any tissue in 4 of 7 infants with sufficient tonsil tissue for the assay. Furthermore, this assay employed total mononuclear cells and flow cytometric analysis revealed that proportions of CD4+ T cells of total CD45+ mononuclear cells were lower in palatine tonsil than other lymphoid tissues ([Figure S3](#SD1){ref-type="supplementary-material"}), indicating a potential highly infectious tissue-associated virus titer in palatine tonsil. Additionally, two viremic animals, CH65-treated animal LH07 and tri-mAb-treated animal LK81, exhibited undetectable tissue-associated infectious virus titers.

Proviral loads, tissue-associated infectious virus titers, and tissue viral RNA levels in PBMCs (preinfection, 2 and 8 weeks post-infection), GI tract tissues, and lymphoid tissues in non-viremic, SHIV-challenged infant RMs were also measured to assess the possibilities of abortive infection or low level replication in the non-viremic infant RMs ([Figure 5](#F5){ref-type="fig"}). Several animals with undetectable plasma SHIV RNA loads throughout the study including DH378-treated animals LG73 and LI46, and CH65-treated animal LH19, had detectable SHIV proviral DNA loads in various tissues at similar levels to those measured from animals with detectable plasma SHIV RNA loads ([Figure 5A](#F5){ref-type="fig"}). To confirm the presence of tissue-associated virus in these non-viremic animals, the SHIV proviral envelopes were amplified by PCR of genomic DNA (gDNA) from submandibular LN CD4+ T cells of LH19 and LG73, sequenced to demonstrate the presence of full-length envelope open reading frames, and expressed as pseudovirus in the SG3∆*env* backbone to assess *env* infectious functionality ([Figure 5B](#F5){ref-type="fig"}). Both pseudoviruses were capable of infecting TZM-bl reporter cells with the LH19 and LG73 *env* pseudoviruses eliciting luminescence magnitudes of 571,294 RLU and 176,820 RLU, respectively, which was appreciably higher than that of cell only controls (\~500 RLU).

Thus, 4 infants, at least 1 from each mAb treatment group, had discordance between the presence of detectable plasma viral RNA and CD4+ T cell provirus ([Figure 6A](#F6){ref-type="fig"}). Provirus was observed in CD4+ T cells isolated from non-viremic animals LG73, LI46, and LH19. Alternatively, provirus was not detectable in the viremic animal LK81. Notably, prior to correction for multiple comparisons, tri-mAb-treated infants, but not DH378-treated infants, demonstrated lower magnitude proviral loads in 8 week PBMCs compared to control mAb-treated animals (Wilcoxon test; raw p=0.03; FDR-corrected p=0.18). Taken together, 7/8 CH65- treated control animals, 5/6 DH378-treated animals, and 2/6 tri-mAb-treated animals demonstrated either detectable viremia or proviral loads following oral SHIV challenge ([Figure 6B](#F6){ref-type="fig"}).

Plasma SHIV variant diversity in mAb-treated and orally SHIV-infected infant RMs {#S7}
--------------------------------------------------------------------------------

To assess the potential impact of maternal mAb passive infusion of infants on the genetic bottleneck of mucosal virus transmission and SHIV *env* diversification by peak viremia (2 weeks post challenge), single SHIV variants were isolated from infant RM plasma using single genome amplification (SGA). Of note, the median viral diversity of the SHIV-1157ipd3N4 challenge virus stock was 0.02% (range=0--0.07%), considerably lower than the diversity typically observed in chronically HIV-1-infected humans (\>1% diversity). Viral diversity within each animal was visualized with phylogenetic tree and highlighter plot ([Figure S4](#SD1){ref-type="supplementary-material"}). Distinct SHIV transmitted/founder (T/F) variants present in plasma isolated at peak viremia (2 weeks post challenge) were enumerated using previously established criteria ^[@R43]^, requiring that a genotypically distinct variant contain 2 novel mutations (to minimize the possibility of recombination yielding false results), and that these mutations be observed in at least 2 SGAs (to minimize the effects of PCR-related mutation). A similar number of distinct SHIV variants were present in plasma at peak viremia between control mAb-treated RMs ([Table 2](#T2){ref-type="table"}; n=8; median variants isolated=2.5; range=0--4) and DH378 mAb-treated animals (n=6; median variants isolated=0.5; range=0--2; Wilcoxon test; raw p=0.16). However, plasma SHIV diversity at peak viremia was lower in tri-mAb-treated RMs (n=6; median variants isolated=0; range=0--1; Wilcoxon test; raw p=0.05), indicating a possible sieve effect of the tri-mAb treatment on oral SHIV acquisition. SHIV *env* amplicons from all infants in a single tree rooted to the SHIV- 1157ipd3N4 challenge virus *env* revealed that the tri-mAb-treated RMs LK72 and LK81 are more homogenous compared to the other 2 infusion groups ([Figure S5](#SD1){ref-type="supplementary-material"}).

Discussion {#S8}
==========

Despite daily chronic oral exposure to HIV for up to 2 years, only \~10% of breastfeeding infants of untreated HIV-infected mothers acquire HIV ^[@R11]^. Furthermore, postnatally HIV-infected infants demonstrate slower disease progression compared to in utero or peripartum infected infants ^[@R44]^. Therefore, a better understanding of the naturally protective components in breast milk of HIV-infected mothers, including milk antibodies, could aid in the development of effective vaccination strategies aimed at reducing MTCT and other modes of HIV acquisition. HIV-specific neutralizing antibodies have been shown to reduce chronic viral loads and enhance host anti-HIV B cell responses in orally challenged, infected RM infants ^[@R45]^. Additionally, post-exposure infusion of an anti-HIV bNAb cocktail within 24hrs after infection was capable of SHIV clearance in infant RMs ^[@R26]^. While tier 1 virus weakly-neutralizing antibodies predicted reduced MTCT rate ^[@R32]^, maternal plasma HIV-specific antibody potency and breadth has recently been associated with increased incidence of vertical transmission ^[@R46]^. Yet, HIV-specific ADCC-mediating antibody levels have been associated with reduced vertical transmission rates and infant mortality ^[@R22],\ [@R23]^. Thus, the potential protective effects of maternal breast milk antibodies lacking neutralization breadth and potency remains uncertain. In this study, we sought to probe the protective capabilities of several weakly or non-neutralizing, polyfunctional milk mAbs previously isolated from a cohort of HIV-infected Malawian women in an infant RM passive infusion and oral SHIV challenge model. The three maternal mAbs selected for inclusion in this study were intended to represent mAbs exhibiting various anti-HIV functionalities (ADCC, tier 1 and weak tier 2 neutralization, dendritic cell-virus binding inhibition, epithelial cell-virus binding inhibition) and HIV Env specificities (C1, V3, CD4-blocking). The treatment groups in this study were designed to assess whether a CD4-blocking mAb with tier 1 and weak autologous tier 2 neutralization (DH378 mAb treatment group), or a polyclonal mAb infusion with multiple antiviral functionalities (tri-mAb treatment group) could contribute to protection.

As expected, serum from groups treated with mAbs DH377 and/or DH378 exhibited neutralization against tier 1 virus, MW965, and serum from groups treated with mAb DH382 exhibited ADCC against the challenge SHIV. The lack of SHIV-1157ipd3N4 neutralization by DH378-infused animals was expected as mAb levels of DH378 did not reach the IC~50~ for SHIV-1157ipd3N4 neutralization (79µg/mL), given the limitation of the infusion volume in infant RMs. Of note, this in vitro estimation of neutralization potency in TZM-bl reporter cells does not necessarily directly predict the in vivo effect of infused mAbs ^[@R47]^. Several viremic animals treated with the control mAb developed neutralization responses against MW965 and ADCC responses against the challenge SHIV by week 8. Yet, only one viremic animals from both anti-HIV mAb-treated groups exhibited adaptive ADCC responses at week 8, which could indicate mAb blocking of immunogenic epitopes.

Plasma viremia was assessed to classify the extent to which anti-HIV breast milk mAb-treated animals were protected from systemic SHIV acquisition relative to the control mAb CH65-infused animals. Importantly, as maternal mAbs employed in this study did not coevolve with the challenge virus, which would be the case in the natural setting of infant HIV-1 exposure, the observed protection facilitated by these mAbs may underrepresent that which would occur against autologous viral strains. Both the DH378-treatment and the tri-mAb cocktail treatment groups had a lower number of viremic animals compared to the control mAb-infused group (6/8 animals viremic), with only 3/6 and 2/6 animals becoming viremic, respectively ([Figure 3](#F3){ref-type="fig"}). Yet, this potential partial protection mediated by milk mAbs lacked statistical significance when compared to controls. Additionally, peak VLs, but not set point VLs, in DH378-treated, viremic animals were significantly higher than that of control animals and this difference was not attributable to more protective MHC-types in the control animals ([Table 1](#T1){ref-type="table"}). This apparent mAb effect on plasma VL could be due to selection of more fit variants with subtle differences in time to peak VL not appreciated by our sampling schedule, and/or antibody- dependent enhancement of viral infection of target cells . Antibody-dependent enhancement of HIV infection, observed as increased T/F variants and/or higher infection rates, has been previously associated with the presence of poorly-neutralizing, HIV-specific antibodies similar to mAb DH378 ^[@R48]^.. However, peak VLs in the tri-mAb-treated, viremic animals were not elevated over those in control animals, indicating that a cocktail of functionally diverse mAbs may negate the potential effects of a single mAb on viral replication. Additionally, tri-mAb-treated animal LK81 demonstrated the lowest peak and set point viral loads observed in any viremic animal ([Figure 3](#F3){ref-type="fig"}). This enhanced viral control post-acquisition may be attributable to the animal MHC background with 2 protective MHC alleles, Mamu-A001 and Mamu-B047a ^[@R34]--[@R41]^, however, other viremic animals sharing the Mamu-A001 allele, including LK72 with 2 protective alleles, did not demonstrate notably lower viral loads ([Table 1](#T1){ref-type="table"}). Furthermore, these MHC alleles are not associated with decreased peak viral loads ^[@R34],\ [@R40]^.

Tissue-associated virus was assessed in viremic animals at 8 weeks via multiple approaches to fully characterize the state of the tissue-associated virus load within lymphoid and GI tract tissues ([Figure 4](#F4){ref-type="fig"}). The size of the resting memory cell latent reservoir in these infant RMs was not directly assessed due to limitations of cell numbers. While limited differences in measures of virus-infected cells were observed between most infant RMs regardless of treatment groups, tri-mAb-treated animal LK81 did not have detectable proviral loads or tissue mononuclear cell-associated infectious viral titers, and only low levels of active viral transcription in only 2 of 5 tissues tested. This finding is consistent with the low plasma viremia observed in this animal, and potentially attributable to the pre-existing tri-mAb anti-HIV functionalities. While our characterizations of tissue-associated virus were otherwise similar between treatment groups, tissue mononuclear cell-associated infectious viral titers indicated that the tonsillar tissue had heightened infectious SHIV levels compared to other lymphoid and GI tissues. This result aligns with previous reports indicating the susceptibility of tonsillar tissue as a portal of HIV entry and amplification ^[@R49]^, and further suggests that the tonsils may be a key anatomical site for strategies seeking to prevent or treat HIV infections, particularly through the oral route.

Interestingly, we observed high proviral loads in a range of tissues from several control and DH378 mAb-treated non-viremic animals ([Figure 5](#F5){ref-type="fig"}). These findings indicate either abortive or very low level SHIV infection. Generation of pseudoviruses containing 2 proviral envelope genes (*env*) isolated from these animals demonstrated that they were capable of infection in vitro, indicating functional envelope genes of these proviruses. However, the viability of the full length provirus was not assessed due to inability to amplify the full genome. Notably, detectable provirus was not observed in CD4+ T cells isolated from any tissues of all non-viremic, tri-mAb-treated animals. This finding indicates that the tri-mAb cocktail successfully prevented or eliminated even abortive infection in these animals. Alternatively, Liu *et al.* recently demonstrated that passive bNAb infusion mediating complete protection from subsequent intravaginal SHIV challenge in RMs did not prevent initial virus acquisition and proliferation in distal tissues, but rather that the bNAb successfully cleared this infection by around 10 days post-challenge ^[@R50]^. Similarly, Hessell *et al* reported that 24-hour post exposure passive infusion of an anti-HIV bNab cocktail in SHIV-challenged infant RMs cleared virus from blood and tissues ^[@R26]^. Hessell *et al* also demonstrated that passive infusion of RMs with a V2i-specific mAb prior to repeated SHIV challenges reduced blood viral loads and lymphoid tissue proviral loads ^[@R51]^. Thus, perhaps the various anti-SHIV functionalities mediated by the tri-mAb treatment in this study similarly cleared the initial infection of distal tissues. To determine whether the tri-mAb treatment prevented initial SHIV acquisition in these animals or mediated clearance of SHIV in distal tissues, additional work characterizing the viral populations present in distal lymphoid tissues at various early time points post-challenge is necessary. Regardless of the mechanism leading to uninfected distal tissues, we speculate that the potent ADCC-mediating mAb, DH382, may have played a pivotal role since the weakly-neutralizing DH378 mAb treatment alone failed to similarly limit tissue-associated proviral loads.

Finally, the SHIV diversity at peak viremia in infant RMs was measured to assess the capability of these milk mAbs to limit the number of transmitted/founder (T/F) variants transmitted across the mucosa and/or early SHIV diversification after oral challenge ([Table 2](#T2){ref-type="table"}). The fewer distinct SHIV variants isolated from tri-mAb-treated animals compared to control mAb-treated animals indicates that this cocktail of maternal mAbs successfully limited the number of SHIV variants capable of sustaining infection in infant RMs. As DH378 mAb-treated infant RMs exhibited similar numbers of SHIV plasma variants compared to control mAb-treated animals, again the combination of distinct antibody functions, with a particular emphasis on ADCC, is likely important for reducing SHIV variant transmission. Of note, as only day 14 post challenge SHIV variants were isolated to assess viral diversity, the mechanism of mAb-mediated control of SHIV diversity may include limiting the number of initial T/F variants, minimizing post infection diversification, or a combination of both.

In conclusion, a combination of mAbs with diverse Env epitope specificity, weak neutralization capabilities, and ADCC functionality, appeared effective at lowering the number of T/F SHIV variants, and potentially SHIV levels in circulating CD4+ T cells and tissues in SHIV-challenged infant RMs. Taken together, these trends suggest that polyclonal non-broadly neutralizing maternal mAbs with multiple functionalities, and particularly ADCC, may contribute to the naturally limited MTCT during breastfeeding, potentially through inhibition of initial virus acquisition at mucosal sites or through rapid viral clearance in the tissues. A better understanding of the mechanism of this protection as well as other maternal and/or infant factors that contribute to the relative protection of infants in the setting of breastfeeding may lead to more effective pediatric HIV therapeutic and prophylactic vaccine design strategies.

Materials and Methods {#S9}
=====================

More detailed description of experimental methods provided in Supplemental Methods.

Study Design {#S10}
------------

Twenty infant rhesus macaques (RM; 1--2 weeks old) were IV infused with either 10mg/kg anti-HIV Env gp120 monoclonal antibody (mAb) DH378 (n=6), 10mg/kg anti-influenza HA mAb CH65 (n=6), 30mg/kg α-HA mAb CH65 (n=2), or 30mg/kg of a tri-mAb cocktail composed of stoichiometric equivalents of 3 anti-HIV Env gp120 mAbs (n=6)---DH377, DH378, and DH382---one hour prior to the first oral SHIV challenge. Animals were subjected to 3 oral challenges per day for 3 consecutive days consisting of 5,000 TCID~50~ SHIV-1157ipd3N4 (NIH AIDS Reagent Program) incubated in 1mL of RPMI containing 1--3µg/mL DH378, CH65, or tri-mAb cocktail for 15 minutes, followed by dilution in \~10mL formula feed to simulate oral acquisition via breastfeeding. Animals were re-infused with their respective antibody infusions one week after the initial infusion. Blood and saliva (via weck cell sponges) were collected before each infusion, 1 hour after each infusion, 1 day after each infusion, and at weeks 2, 4, 6, and 8 of the study. All animals were necropsied at week 8 of the study and tissues were collected.

Production of infusion mAbs {#S11}
---------------------------

Infusion mAbs were obtained through antigen-specific B cell sorting and Ig variable gene amplification, as previously described ^[@R20]^, and produced through transient transfection either by the manufacturer Catalent (DH378; Catalent) or at the Duke Human Vaccine Institute in Expi293 cells (DH377, DH382, CH65), as previously described ^[@R52]^.

HIV-1 Neutralization in TZM-bl Cells {#S12}
------------------------------------

Neutralizing antibody titers were measured by the reduction in Tat-regulated Luc reporter gene expression in a TZM-bl (NIH AIDS Reagent Program) reporter cell assay, as previously described ^[@R53]^.

Tissue Mononuclear Cell Viral Coculture {#S13}
---------------------------------------

Tissue-associated infectious virus titer was assessed through Tat-regulated Luc-F reporter gene expression to quantify infection of TZM-bl reporter cells after coculture with serial dilutions of tissue mononuclear cells isolated from RMs.

Plasma Viral RNA Load Quantification {#S14}
------------------------------------

Reverse transcriptase quantitative PCR was performed to determine the SHIV-1157ipd3N4 RM plasma RNA load, as previously described ^[@R54]^.

Mononuclear Cell Provirus Quantification {#S15}
----------------------------------------

RM CD4+ T cell-associated genomic DNA (gDNA) was isolated from various GI and lymphoid tissues with the QIAaMP DNA/RNA extraction kit (Qiagen) and quantified using the Biorad QX200 droplet digital PCR System according to the manufacturer instructions (Biorad) with SHIV *gag* specific primers and probe and a commercially available human TERT-specific reference assay (Biorad). The SHIV proviral load in SHIV copies/million CD4+ T cells was calculated by dividing the SHIV DNA copy number by the TERT copy number divided by 2 multiplied by 10^6^ cells.

Measurement of virus-specific IgG levels in plasma and saliva {#S16}
-------------------------------------------------------------

Antibody concentrations in plasma and saliva were identified with Enzyme-linked immunosorbent assays (ELISA), as previously described ^[@R28]^.

Antibody Dependent Cellular-Cytotoxicity {#S17}
----------------------------------------

ADCC activity of the purified mAbs and peripheral serum samples was determined by a luciferase-based cell killing assay with *Renilla* luciferase reporter gene encoding SHIV1157-ipd3N4-IMC, CEM.NKR~CCR5~ target cells (NIH AIDS Reagent Program), and PBMCs from a healthy HIV-seronegative donor, as previously described ^[@R29],\ [@R32]^.

Flow Cytometry {#S18}
--------------

RM PBMCs or tissue mononuclear cells were stained with a panel of fluorochrome-conjugated antibodies and either phenotyped using an LSRII flow cytometer or bulk sorted into CD4+ and CD8+ T cells using a FACS Aria II cytometer (BD Biosciences). CD4+ and CD8+ T cells were positively selected from isolated tissue mononuclear cells by sequential selection of lymphocytes, FSC and SSC singlets, viable cells, CD45+ leukocytes, CD3+ T cells, and CD4+ vs CD8+ T cells. Data analysis was performed using FlowJo software (TreeStar).

In Situ Hybridization {#S19}
---------------------

In situ hybridization for the detection and quantification of SHIV gag RNA in formalin-fixed tissue blocks was performed using the Affymetrix protocol according to manufacturer instruction (Affymetrix). Tissue blocks were stained for CD3, DAPI, and SHIV gag RNA and imaged on slides with a Leica TCS SP8 confocal microscope. The number of SHIV RNA producing cells was reported as the number of SHIV *gag* RNA+ cells per 1,000 CD3+ T cells.

Transmitted/Founder Analysis {#S20}
----------------------------

Transmitted/Founder (T/F) viral sequences in plasma were obtained by single genome amplification (SGA) through nested reverse transcriptase PCR with subsequent direct amplicon sequencing, as previously described ^[@R55]^. Sequence alignments and phylogenetic trees were constructed using clustalW and Highlighter plots were created using the tool at [www.lanl.gov](http://www.lanl.gov/).

To identify and enumerate T/F variants, clusters of related sequences were visually analyzed using phylogenetic trees (Figtree v1.4) and sequences containing \<2 mutations were considered a single variant. Variants containing ≥2 mutations were considered as progeny of distinct T/F genomes. Potential G-A hymermutations caused by APOBEC 3G/3F were identified using Hypermut algorithm 2.0 and were reverted for analysis if there were ≤ 2 present. Sequences that had \>3 potential APOBEC 3G/3F mutations were not considered for T/F analysis (Hypermut, [http://www.hiv.lanl.gov](http://www.hiv.lanl.gov/)). Sequence clusters of ≥ 2 sequences with ≥2 shared mutations were considered as distinct T/F variants.

Provirus env cloning and pseudovirus preparation {#S21}
------------------------------------------------

SHIV *env* amplification from genomic DNA (gDNA) extracted from infant RM CD4+ T cells was done through bulk nested PCR and cloning into pcDNA3.1/V5-His-Topo (Invitrogen). Pseudovirus was produced via cotransfection of the SHIV *env* plasmid and a plasmid containing a subtype B *env* deficient HIV genome (SG3∆*env*) in 293T cells (Invitrogen) as previously described ^[@R53]^. Pseudotyped virus infectivity was screened by TZM-bl cell infection and Tat-regulated luminescence with the Bright-Glo luciferase reagent (Promega).

Statistical Analysis {#S22}
--------------------

Statistical tests were performed with SAS v9.4 (SAS Institute). Comparisons of viral load, proviral load (copies/million cells), and the number of T/F variants in infants from each mAb treatment group were performed using the exact Wilcoxon test. The proviral load (binary designation), and the number of infants with detectable SHIV in each mAb treatment group were compared with Fisher's exact test. False discovery rate (FDR) p-value correction was used to correct for multiple comparisons. A p-value of \<0.05 (two-tailed) was considered as significant for all analyses.
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![Infant RM passive mAb infusion and oral SHIV challenge study design.\
**A)** Functional characterization of maternal breast milk mAbs selected for passive infusion into infant RMs. MAbs were selected based on diverse functionality, including Env binding specificity and ADCC, inhibition of dendritic cell virus transfer, inhibition of epithelial cell-virus binding, and virus neutralization functionalities. **B)** Timeline for passive mAb infusion and SHIV-1157ipd3N4 challenge of infant RMs. Twenty infant RMs (1--2 weeks old) were systemically infused with the indicated mAbs and subsequently orally challenged after 1 hour with 5,000 TCID~50~ of the tier 2 SHIV-1157ipd3N4 in formula feed to mimic infant oral viral exposure during breast feeding. Animals were reinfused 7 days after the first mAb infusion with the same mAb dose to sustain systemic Ab titers. Animals were necropsied at 8 weeks after challenge and lymphatic and GI tract tissues were collected.](nihms-981029-f0001){#F1}

![The kinetics of passively infused mAbs and anti-SHIV Ab function in passively breast milk mAb-infused, SHIV-challenged infant RM serum and saliva.\
Concentrations of infused mAbs in **A-C)** serum and **F-H)** saliva from pre-infusion to 8 weeks post infusion are depicted for control mAb-treated (**A,F**; CH65; red), DH378 mAb-treated (**B,G**; DH378; blue), and tri-mAb-treated (**C,H**; DH378, DH377, DH382; green) infant RMs. **D)** Neutralizing Ab levels in serum reported as ID~50~ against the tier-1 virus MW965 from pre-infusion to 8 weeks post challenge. **E)** ADCC-mediating Ab levels in serum reported as endpoint titer against SHIV-1157ipd3N4 at preinfusion, 1 week ([1 day]{.ul} after 2^nd^ mAb infusion), and 8 weeks post challenge. Black arrows indicate systemic mAb infusions at days 0 and 7. ND indicates not detectable.](nihms-981029-f0002){#F2}

![Infection rates and plasma viral loads of passively breast milk mAb-infused, SHIV-challenged infant RMs.\
**A)** Proportion of viremic RMs with 6/8 control mAb-treated RMs (red), 3/6 DH378 mAb-treated RMs (blue; Fisher's exact test; FDR-corrected p=0.58), and 2/6 tri-mAb-treated RMs (green; Fisher's exact test; FDR-corrected p=0.55) demonstrating viremia as defined by a detectable plasma viral RNA load at any tested time point. **B)** Plasma viral RNA loads in mAb treated, orally SHIV challenged infant RMs. \* indicates significantly higher 2 week post infection plasma viral RNA loads in DH378 mAb-treated RMs compared to CH65-treated RMs (Wilcoxon test; FDR-corrected p=0.05). Animals with HLA type A001 or B17 are annotated appropriately in the legend.](nihms-981029-f0003){#F3}

![Tissue-associated SHIV measures in mononuclear cells isolated from lymphoid and GI tissues of viremic infant RMs 8 weeks post passive breast milk mAb infusion and oral SHIV challenge.\
**A)** CD4+ T cell proviral DNA loads reported as copy number/million CD4+ T cells in lymphoid and GI tissue mononuclear cells and **B)** number of SHIV RNA producing CD3+ T cells in lymphoid and GI tissue blocks reported as the number of SHIV Gag RNA+ cells per 1,000 CD3+ T cell were measured for control mAb-treated (red), DH378 mAb-treated (blue), and tri-mAb-treated RMs (green) through ddPCR and in situ hybridization, respectively. ND indicates not detectable. **C)** Representative images of stained tissue blocks demonstrating active SHIV RNA transcription within a Peyer's Patch (LI40 jejunum) and in CD3+ T cells in lymphoid tissue (LI40 lingual tonsil) employed to assess the number of SHIV RNA transcribing cells within lymphoid and GI tissues. Blue, green, and red depict nuclear, CD3, and SHIV Gag RNA staining, respectively. **D)** Tissue-associated infectious SHIV-1157ipd3N4 titers measured through tissue mononuclear cell coculture with TZM-bl reporter cells. Reported titers represent the estimated minimum number of mononuclear cells required to yield detectable infection (cutoff defined by mononuclear cells from unchallenged RM negative controls) of the TZM-bl cells in 50% of replicates. The cutoff for The limit of detection varied for each sample and was determined by mononuclear cell availability. NT indicates untested samples.](nihms-981029-f0004){#F4}

![Tissue-associated SHIV DNA in CD4+ T cells isolated from lymphoid and GI tissues of non-viremic infant RMs 8 weeks post passive breast milk mAb infusion and oral SHIV challenge.\
**A)** Proviral DNA loads reported as copy number/million CD4+ T cells in lymphoid and GI tissue mononuclear cells were measured for control mAb-treated (red), DH378 mAb-treated (blue), and tri-mAb-treated RMs (green) through ddPCR. ND indicates not detectable. **B)** Highlighter plot alignments of 2 amplified SHIV *env* sequences obtained through SGA of extracted DNA from CD4+ T cells isolated from LH19 and LG73 submandibular lymph nodes compared to the SHIV-1157ipd3N4 *env* stock sequence. Colored lines indicate nucleotide mismatches compared to the SHIV stock. These *envs* were cloned and subsequently incorporated into pseudoviruses with a SG3∆*env* backbone through co-transfection in 293T cells. Pseudovirus infectivity was estimated in TZM-bl reporter cells as RLUs compared to cell-only controls (\<500 RLU). Pseudoviruses expressing *env* isolated from LH19 and LG73 demontstrated infectious capability with 571,294 RLU and 176,820 RLU magnitudes, respectively.](nihms-981029-f0005){#F5}

![Summary of SHIV detection and proportion of animals with detectable cell-free or cell-associated SHIV in breast milk mAb-infused, orally SHIV-challenged infant RMs.\
**A)** Binary indication of detectable plasma SHIV RNA, peripheral CD4+ T cell SHIV provirus, and tissue CD4+ T cell SHIV provirus detection. For each animal, SHIV detection methods with detectable SHIV in any tested tissue or at any timepoint were indicated with a red "+", while those with undetectable values in all tested tissues and at all timepoints were indicated with a grey "-". **B)** Proportion of animals with detectable cell-free or cell-associated SHIV as defined by detectable SHIV plasma RNA, SHIV provirus in tissues or PBMCs, tissue mononuclear cell-associated infectious SHIV titers, or SHIV RNA-transcribing cells.](nihms-981029-f0006){#F6}

###### 

MHC alleles present in control mAb-, DH378 mAb-, and tri-mAb-treated and SHIV-1157ipd3N4-challenged infant RMs.

  Animal ID   Treatment Group    Infection Status   Mamu-A            Mamu-B      Mamu-DRB                            
  ----------- ------------------ ------------------ ----------------- ----------- ----------- ----------- ----------- -----------
  **LH07**    **Control mAb**    **Viremic**        **A001**          **A008**    **B055**    **B024a**   **DR01a**   **DR14a**
  **LH20**    **A002a**          [**A004**]{.ul}    **B001a**         **B001a**   **DR01a**   **DR016**               
  **LI52**    **A006**           **A224a**          **B015a**         **B017a**   **DR03f**   **DR016**               
  **LL15**    **A007**           **A008**           **B001a**         **B055**    **DR04a**   **DR06**                
  **LH19**    **Non- viremic**   [**A004**]{.ul}    **A008**          **B021a**   **B047a**   **DR01a**   **DR06**    
  **LL16**    [**A004**]{.ul}    **A008**           **B012b**         **B080**    **DR03a**   **DR11a**               
  **LG80**    **DH378 mAb**      **Viremic**        [**A004**]{.ul}   **A011**    **B055**    **B012b**   **DR11c**   **DR02'**
  **LI59**    **A001**           [**A004**]{.ul}    **B024a**         **B048**    **DR03a**   **DR03f**               
  **LI40**    **A002a**          [**A004**]{.ul}    **B012a**         **B012a**   **DR03a**   **DR03f**               
  **LG73**    **Non- viremic**   **A001**           **A011**          **B055**    **B001a**   **DR01a**   **DR04a**   
  **LI46**    **A002a**          **A002a**          **B048**          **B048**    **DR04a**   **DR03f**               
  **LK72**    **Tri-mAb**        **Viremic**        **A001**          **A002a**   **B024a**   **B012a**   **DR03f**   **DR03f**
  **LK81**    **A001**           **A008**           **B043a**         **B047a**   **DR01a**   **DR13a**               
  **LK79**    **Non-viremic**    **A002a**          [**A004**]{.ul}   **B001a**   **B012a**   **DR11a**   **DR03f**   
  **LK82**    **A002a**          **A001**           **B001a**         **B001a**   **DR11a**   **DR01a**               
  **LM19**    [**A004**]{.ul}    [**A004**]{.ul}    **B001a**         **B002**    **DR03a**   **DR13a**               
  **LM20**    [**A004**]{.ul}    **A008**           **B015a**         **B015b**   **DR03a**   **DR01a**               

Dark and light grey shading indicates MHC alleles previously reported as highly^[@R33]--[@R40]^ or mildly^[@R33],[@R35],[@R38],[@R39]^ associated with lower plasma set point viral load, respectively.

Underlining indicates MHC alleles associated with higher plasma viral load at set point^[@R41]^.

###### 

Diversity of SHIV-1157ipd3N4 variants in serum isolated 1 week post initial oral challenge from control mAb-, DH378 mAb-, or tri-mAb-treated infant RMs.

  Control mAb (Animal ID)      \# of Variants   SGA Sequences per Animal   DH378 mAb (Animal ID)            \# of Variants   SGA Sequences per Animal   Tri-mAb (Animal ID)              \# of Variants   SGA Sequences per Animal
  ---------------------------- ---------------- -------------------------- -------------------------------- ---------------- -------------------------- -------------------------------- ---------------- --------------------------
  LI52                         **4**            **33**                     **LG80**                         **2**            **30**                     **LK72**                         **1**            **25**
  LD65                         **3**            **36**                     **LI59**                         **2**            **18**                     **LK81**                         **1**            **32**
  LH20                         **3**            **23**                     **LI40**                         **1**            **21**                     **LK79**                         **0**            **-**
  LL15                         **3**            **27**                     **LI46**                         **0**            **-**                      **LK82**                         **0**            **-**
  LH07                         **2**            **16**                     **LG73**                         **0**            **-**                      **LM19**                         **0**            **-**
  LD77                         **1**            **42**                     **LI68**                         **0**            **-**                      **LM20**                         **0**            **-**
  LH19                         **0**            **-**                                                                                                                                                     
  LL16                         **0**            **-**                                                                                                                                                     
                                                                                                                                                                                                          
  Median (Range) \# Variants   **2.5 (0--4)**                              **Median (Range) \# Variants**   **0.5 (0--2)**                              **Median (Range) \# Variants**   **0 (0--1)**     
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